Q-omics provides the consensus-scored RFXANK profile across patient tissues and cancer cell-line models. RFXANK expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RFXANK is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, RFXANK RNA expression shows 19,232 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where RFXANK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFXANK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFXANK survival associations across molecular data types. RFXANK RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFXANK RNA expression–survival associations across cancer types. High RFXANK expression shows unfavorable associations in ACC, KICH, LIHC, LGG and LAML, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RFXANK RNA expression.
This table summarizes RFXANK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RFXANK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFXANK shows higher tumor expression in KIRC, BLCA, COAD, LIHC, KIRP and HNSC. The KIRC box plot shows higher RFXANK RNA expression in tumor versus normal tissue (log2 FC = +0.755, t-test p < 0.001).
This table shows molecular features associated with RFXANK in patient tissues and cancer cell lines. In patient samples, RFXANK shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RFXANK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
